All Stories

  1. Oral solid lipid nanoparticles of etoposide enable metronomic-like therapy with reduced toxicity in MYCN-amplified neuroblastoma
  2. Squalene-adenosine nanoparticles enhance cardioprotection in myocardial infarction: Efficacy and mechanistic insights
  3. Intranasal delivery of lipid-based nanoparticles for the treatment of neurodegenerative diseases: advances, challenges and future perspectives
  4. Surface decoration of solid lipid nanoparticles with cyclic RGD peptides for precision therapy in high-risk neuroblastoma
  5. Targeting neuroinflammation in Parkinson's Disease: Immunomodulatory effects of a Hyaluronic Acid-Based Nanoreinforced Hydrogel Loaded with GDNF and Mesenchymal Stem cells
  6. 3D-printed polycaprolactone scaffolds functionalized with poly(lactic-co-glycolic) acid microparticles enhance bone regeneration through tunable drug release
  7. Targeting tumor microenvironment with RGD-functionalized nanoparticles for precision cancer therapy
  8. RNA delivery technologies: From concept toward the clinic
  9. RNA-loaded nanoparticles for the treatment of hematological cancers
  10. Fifty years of sciences with Patrick Couvreur
  11. Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics
  12. Correction: Biosafety evaluation of etoposide lipid nanomedicines in C. elegans
  13. Biosafety evaluation of etoposide lipid nanomedicines in C. elegans
  14. Lipid nanoparticles for siRNA delivery in cancer treatment
  15. Self-assembled lipid–prodrug nanoparticles
  16. Cardiac tissue engineering for myocardial infarction treatment
  17. Hydrogels for brain repair: application to Parkinson’s disease
  18. Encapsulation of MSCs and GDNF in an Injectable Nanoreinforced Supramolecular Hydrogel for Brain Tissue Engineering
  19. Nanomedicines and cell-based therapies for embryonal tumors of the nervous system
  20. Special issue on the latest advances in regenerative medicine and cancer using drug delivery systems
  21. In vivo biodistribution of edelfosine-loaded lipid nanoparticles radiolabeled with Technetium-99 m: Comparison of administration routes in mice
  22. Isolation methods of large and small extracellular vesicles derived from cardiovascular progenitors: A comparative study
  23. Decoration of Squalenoyl‐Gemcitabine Nanoparticles with Squalenyl‐Hydroxybisphosphonate for the Treatment of Bone Tumors
  24. Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
  25. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment
  26. Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction
  27. Optimization of a GDNF production method based on Semliki Forest virus vector
  28. Special Issue “A perspective of drug delivery and translational research in Europe”
  29. Extracellular Vesicle-Based Therapeutics for Heart Repair
  30. SPION and doxorubicin-loaded polymeric nanocarriers for glioblastoma theranostics
  31. Morphology, gelation and cytotoxicity evaluation of D-α-Tocopheryl polyethylene glycol succinate (TPGS) – Tetronic mixed micelles
  32. Improving the genistein oral bioavailability via its formulation into the metal–organic framework MIL-100(Fe)
  33. Sorting hidden patterns in nanoparticle performance for glioblastoma using machine learning algorithms
  34. Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma
  35. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice
  36. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy
  37. Nanomedicine and drug delivery systems in cancer and regenerative medicine
  38. Co-encapsulation of superparamagnetic nanoparticles and doxorubicin in PLGA nanocarriers: Development, characterization and in vitro antitumor efficacy in glioma cells
  39. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine
  40. Long-Term Engraftment of Human Cardiomyocytes Combined with Biodegradable Microparticles Induces Heart Repair
  41. Micro- and nanotechnology approaches to improve Parkinson's disease therapy
  42. Therapeutic Opportunities in Neuroblastoma Using Nanotechnology
  43. Advances in Parkinson’s Disease: 200 Years Later
  44. Biocompatible porous metal-organic framework nanoparticles for gentamicin vectorization
  45. NRG1 PLGA MP locally induce macrophage polarisation toward a regenerative phenotype in the heart after acute myocardial infarction
  46. Nanomedicines for Pediatric Cancers
  47. Oral nanoencapsulated ET causes regression of lung metastases in models of osteosarcoma
  48. Heart tissue repair and cardioprotection using drug delivery systems
  49. Visualization of hybrid gold-loaded polymeric nanoparticles in cells using SEM
  50. Special Issue: Pharmaceutics and Drug Delivery in Spain
  51. Breaching barriers in glioblastoma: Targeted drug delivery
  52. Breaching barriers in glioblastoma: novel treatment approaches
  53. Hydrogel based approaches for cardiac tissue engineering
  54. Cytokine-loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration
  55. Special issue on biomaterials for tissue engineering
  56. Effectiveness of nanoencapsulated methotrexate against osteosarcoma cells
  57. Transplantation of ADSC combined with neuregulin-microparticles promotes efficient cardiac repair
  58. The combination of DOX and ET is likely to be effective against osteosarcoma.
  59. Nanotechnology-based drug delivery systems for Alzheimer's disease management
  60. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys
  61. Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein
  62. Clinical advances of nanocarrier-based cancer therapy and diagnostics
  63. Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion
  64. Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation
  65. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease
  66. Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies
  67. Reformulating cyclosporine A (CsA): More than just a life cycle management strategy
  68. Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems
  69. A simple approach to obtain hybrid Au-loaded polymeric nanoparticles with a tunable metal load
  70. Lipid nanoparticles for osteosarocma therapy
  71. Tracking the in vivo release of bioactive NRG from PLGA and PEG–PLGA microparticles in infarcted hearts
  72. Lípidos nanoparticles for oral CyA administration
  73. Polymeric Electrospun Scaffolds: Neuregulin Encapsulation and Biocompatibility Studies in a Model of Myocardial Ischemia
  74. Heart regeneration after myocardial infarction using synthetic biomaterials
  75. A Zn azelate MOF: combining antibacterial effect
  76. Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
  77. Lipid nanoparticles protect from edelfosine toxicity in vivo
  78. Edelfosine Lipid Nanoparticles Overcome Multidrug Resistance in K-562 Leukemia Cells by a Caspase-Independent Mechanism
  79. Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
  80. In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
  81. Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy
  82. Cytotoxicity of nanoscaled metal–organic frameworks
  83. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration
  84. Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia
  85. Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems
  86. Efficacy of edelfosine lipid nanoparticles in breast cancer cells
  87. Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia
  88. Injectable alginate hydrogel loaded with GDNF promotes functional recovery in a hemisection model of spinal cord injury
  89. A simple and robust high-performance liquid chromatography coupled to a diode-array detector method for the analysis of genistein in mouse tissues
  90. Adipose-derived stem cells combined with Neuregulin-1 delivery systems for heart tissue engineering
  91. Vascular endothelial growth factor‐loaded injectable hydrogel enhances plasticity in the injured spinal cord
  92. Biographies featuring the special issue editors Dr. M.N.V. Ravi Kumar, Dr. María J. Blanco-Prieto and D.N. Waterhouse
  93. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines
  94. Nanotheraputics
  95. Gentamicin-Loaded Nanoparticles Are Effective against Brucella melitensis
  96. Ultra high performance liquid chromatography–tandem mass spectrometry method for cyclosporine a quantification in biological samples and lipid nanosystems
  97. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system
  98. Editorial
  99. PEGylated-PLGA microparticles containing VEGF for long term drug delivery
  100. Brain Drug Delivery Systems for Neurodegenerative Disorders
  101. Lipid nanoparticles for cancer therapy: state of the art and future prospects
  102. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin
  103. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles
  104. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
  105. Vascular Endothelial Growth Factor-Delivery Systems for Cardiac Repair: An Overview
  106. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma
  107. Development and validation of ultra high performance liquid chromatography–mass spectrometry method for LBH589 in mouse plasma and tissues
  108. Angiogenic therapy for cardiac repair based on protein delivery systems
  109. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease
  110. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections
  111. High Loading of Gentamicin in Bioadhesive PVM/MA Nanostructured Microparticles Using Compressed Carbon-Dioxide
  112. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia–reperfusion model
  113. Lipid raft-targeted therapy in multiple myeloma
  114. In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts
  115. Drug delivery systems for potential treatment of intracellular bacterial infections
  116. Production of highly pure human glycosylated GDNF in a mammalian cell line
  117. Comparative study of A HPLC–MS assay versus an UHPLC–MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems
  118. Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
  119. Antitumor Alkyl Ether Lipid Edelfosine: Tissue Distribution and Pharmacokinetic Behavior in Healthy and Tumor-Bearing Immunosuppressed Mice
  120. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres
  121. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization
  122. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor
  123. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections
  124. Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinum‐Based Chemotherapy
  125. Poly(d,l-Lactide-Coglycolide) Particles Containing Gentamicin: Pharmacokinetics and Pharmacodynamics in Brucella melitensis- Infected Mice
  126. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson
  127. Chemical and Biological Factors in the Control of Brucella and Brucellosis
  128. Nanocarriers with Gentamicin to Treat Intracellular Pathogens
  129. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin
  130. Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method
  131. Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamicin
  132. Polymeric Particulates to Improve Oral Bioavailability of Peptide Drugs
  133. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography–electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems
  134. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres
  135. High-performance liquid–chromatographic determination of rifampicin in plasma and tissues
  136. Rapid and simple determination of doxycycline in serum by high-performance liquid chromatography
  137. Development and validation of a liquid chromatographic method for in vitro mupirocin quantification in both skin layers and percutaneous penetration studies
  138. Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture
  139. Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters
  140. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis
  141. In vitro evaluation of gentamicin released from microparticles
  142. Optimization of topical cidofovir penetration using microparticles
  143. PLGA microparticles: possible vehicles for topical drug delivery
  144. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers
  145. In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres
  146. Importance of the test medium for the release kinetics of a somatostatin analogue from poly(?-lactide-co-glycolide) microspheres
  147. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides